Zydus Lifesciences Secures FDA Priority Review for Liver Disease Drug
Decision brief
Answer first · skim in under a minute
Zydus Lifesciences has secured a priority review from the US FDA for its liver disease drug application. This development could significantly impact the company's market positioning.
Zydus Therapeutics’ saroglitazar NDA for primary biliary cholangitis—a progressive autoimmune liver disease—received U.S. FDA Priority Review with a November 27, 2026 PDUFA date. The filing rests on EPICS-III Phase 3 biochemical-response data; approval is not yet granted.
Contents10 sections
Key Takeaways
- On May 28, 2026, Zydus said FDA granted Priority Review to saroglitazar for PBC with or without UDCA depending on response or intolerance.
- PDUFA target action date: November 27, 2026; Zydus cited a potential U.S. launch by March 2027 if approved.
- EPICS-III (NCT05133336) reported 56.7% vs 9.8% biochemical response for saroglitazar vs placebo (difference 48%; p < 0.001).
- Saroglitazar also holds Orphan Drug and Fast Track designations for PBC per the company; it is still investigational in the U.S.
What did FDA Priority Review change for Zydus’s liver disease program?
Priority Review shortens the FDA review clock versus standard review for applications that may offer meaningful improvement for a serious condition. For saroglitazar, Zydus Therapeutics—a wholly owned subsidiary of Zydus Lifesciences—said the NDA seeks use with UDCA in adults with inadequate UDCA response, or as monotherapy when UDCA cannot be tolerated.
Source: PR Newswire — Zydus saroglitazar Priority Review.
What liver disease is PBC, and why does ALP matter?
Primary biliary cholangitis is a rare autoimmune disease that damages bile ducts and can progress to fibrosis, cirrhosis, transplant, or death. Alkaline phosphatase (ALP) and bilirubin are key biochemical markers. Current first-line therapy is ursodeoxycholic acid; many patients still need second-line options when ALP remains elevated.
Saroglitazar is described by Zydus as a novel PPAR α/γ agonist targeting bile-acid toxicity and liver inflammation. That mechanism claim is sponsor framing pending FDA labeling.
What did EPICS-III report?
EPICS-III (NCT05133336) is a multicenter, randomized, double-blind, placebo-controlled Phase 2b/3 study. ClinicalTrials.gov lists the study as COMPLETED with actual enrollment of 196. After dose selection, the Phase 3 portion randomized patients 2:1 to saroglitazar magnesium 1 mg or placebo.
- Biochemical response at Week 52: 56.7% saroglitazar vs 9.8% placebo
- Treatment difference: 48 percentage points (95% CI 35.3–60.8; p < 0.001)
- Composite definition: ALP < 1.67× ULN, ≥15% ALP decrease, and bilirubin ≤ ULN (with Gilbert’s rules as stated)
- Mean ALP change: −33.5% on drug vs +6.5% on placebo (company-reported −40.1% treatment difference)
Registry: ClinicalTrials.gov NCT05133336 (EPICS-III).
How should BD and competitor teams model the November 2026 PDUFA?
Treat November 27, 2026 as a binary regulatory milestone, not a guaranteed approval. If labeled, commercial timing that Zydus floated (U.S. launch by March 2027) still depends on manufacturing, distribution, and payer coverage. Second-line PBC already includes other PPAR and FXR-pathway options in some markets; teams should map labeled endpoints and safety language against those franchises once FDA acts.
Also watch pruritus data carefully: Zydus reported a statistically significant 5-D Itch improvement at Week 24 that was not significant at Week 52 versus placebo.
How does Priority Review interact with Orphan and Fast Track status?
Zydus said saroglitazar already carried Orphan Drug Designation and Fast Track Designation for PBC before Priority Review. Those designations can increase FDA interaction and, for orphan products, offer exclusivity incentives if approved, but none of them equals marketing authorization. Diligence checklists should keep designation status separate from labeled indication text.
For competitive intelligence, map how a PPAR α/γ profile would sit beside existing second-line PBC therapies once FDA publishes labeling. Until then, limit models to the EPICS-III biochemical endpoint and the disclosed safety summary rather than inferred transplant-free survival.
What remains unproven?
Public primaries do not yet show an FDA approval decision, final U.S. prescribing information, or long-term hard outcomes such as transplant-free survival from EPICS-III in this source set. Biochemical response is a surrogate; do not invent survival or market-share percentages. Competitor headlines without allowlisted links were excluded.
Related NovaPharma coverage
- Zydus Therapeutics’ Saroglitazar Receives FDA Priority Review
- EMA Tightens Liver Safety Checks for Tavneos
- FDA Approves Lumasiran for PH1
Frequently Asked Questions
Which Zydus liver disease drug has FDA Priority Review?
Saroglitazar, a PPAR α/γ agonist from Zydus Therapeutics (Zydus Lifesciences), has FDA Priority Review for primary biliary cholangitis (PBC) in adults with inadequate response or intolerance to ursodeoxycholic acid (UDCA).
What is the PDUFA date for saroglitazar?
The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 27, 2026, according to Zydus Therapeutics’ May 28, 2026 announcement.
What did EPICS-III show for saroglitazar in PBC?
In EPICS-III (NCT05133336), 56.7% of saroglitazar-treated patients achieved biochemical response versus 9.8% on placebo at Week 52, a 48 percentage-point difference (95% CI 35.3–60.8; p < 0.001), per the company release supporting the NDA.
Primary Sources
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
